Production of High-Value Proteins under Stringent Cost Constraints-The Case of Hollow Fiber Technology for Cell Culture

被引:1
作者
Tantakitti, Faifan [1 ,2 ]
Pata, Supansa [3 ,4 ]
Laopajon, Witida [3 ,4 ]
Kasinrerk, Watchara [3 ,4 ]
Hidalgo-Bastida, Araida [5 ]
机构
[1] Chiang Mai Univ, Fac Engn, Dept Mech Engn, Chiang Mai 50200, Thailand
[2] Chiang Mai Univ, Ctr Excellence Mat Sci & Technol, Chiang Mai 50200, Thailand
[3] Chiang Mai Univ, Fac Associated Med Sci, Dept Med Technol, Div Clin Immunol, Chiang Mai 50200, Thailand
[4] Chiang Mai Univ, Natl Sci & Technol Dev Agcy, Biomed Technol Res Ctr, Natl Ctr Genet Engn & Biotechnol,Fac Associated Me, Chiang Mai 50200, Thailand
[5] Manchester Metropolitan Univ, Ctr Biomed, Dept Life Sci, Manchester M1 5GD, England
关键词
cost analysis; hemoglobin f; hollow fiber bioreactor; hybridoma; monoclonal antibody production; upstream process; MONOCLONAL-ANTIBODY PRODUCTION; IN-VITRO; GROWTH; PERFUSION;
D O I
10.3390/pr11030889
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
For decades, the benefits of utilizing hollow fiber bioreactors for continuous cell culture to produce monoclonal antibodies have been widely recognized. However, the suitability of this technology for laboratories or centers with limited resources and expertise seeking to expand their production capacity is uncertain, mainly due to unknown cost-effectiveness. In this study, a hollow fiber bioreactor with a 4.7-mL culture volume was used to culture a hybridoma clone producing immunoglobulin G antibody specific to hemoglobin F (HbF). The antibody reached a maximum concentration of 1.22 g/L and totaled 21 mg over a 44-day culture period. This preliminary production data was used to estimate the cost of consumables required for using the hollow fiber bioreactor to produce 130 mg of monoclonal antibodies, which was found to be THB35.8k (880) pound. The cost was slightly more expensive than batch cultivation in typical culture dishes, which ranged from THB27.8 to 30.2k (680 pound to 740). Despite the advantages in terms of reduced hands-on time, shorter production duration, and highly concentrated products, the primary challenges associated with using hollow fiber bioreactors were the cost and availability of the cartridges.
引用
收藏
页数:14
相关论文
共 34 条
  • [1] CONTINUOUS HYBRIDOMA GROWTH AND MONOCLONAL-ANTIBODY PRODUCTION IN HOLLOW FIBER REACTORS SEPARATORS
    ALTSHULER, GL
    DZIEWULSKI, DM
    SOWEK, JA
    BELFORT, G
    [J]. BIOTECHNOLOGY AND BIOENGINEERING, 1986, 28 (05) : 646 - 658
  • [2] Effect of Operating Conditions in Production of Diagnostic Salmonella Enteritidis O-Antigen-Specific Monoclonal Antibody in Different Bioreactor Systems
    Ayyildiz-Tamis, Duygu
    Nalbantsoy, Ayse
    Elibol, Murat
    Deliloglu-Gurhan, Saime Ismet
    [J]. APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2014, 172 (01) : 224 - 236
  • [3] Cadwell John J. S., 2004, American Biotechnology Laboratory, V22
  • [4] Industrial implementation of in vitro production of monoclonal antibodies
    Dewar, V
    Voet, P
    Denamur, F
    Smal, J
    [J]. ILAR JOURNAL, 2005, 46 (03) : 307 - 313
  • [5] The therapeutic monoclonal antibody market
    Ecker, Dawn M.
    Jones, Susan Dana
    Levine, Howard L.
    [J]. MABS, 2015, 7 (01) : 9 - 14
  • [6] Hollow fiber bioreactor technology for tissue engineering applications
    Eghbali, Hadis
    Nava, Michele M.
    Mohebbi-Kalhori, Davod
    Raimondi, Manuela T.
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2016, 39 (01) : 1 - 15
  • [7] Gao Yiling, 2018, J Immunoassay Immunochem, V39, P351, DOI 10.1080/15321819.2018.1515775
  • [8] Selection and isolation of cells for optimal growth in hollow fiber bioreactors
    Gramer, MJ
    Britton, TL
    [J]. HYBRIDOMA, 2000, 19 (05): : 407 - 412
  • [9] Gramer MJ, 1999, BIOTECHNOL BIOENG, V65, P334, DOI 10.1002/(SICI)1097-0290(19991105)65:3<334::AID-BIT11>3.0.CO
  • [10] 2-L